A number of firms have modified their ratings and price targets on shares of Qiagen NV (NASDAQ: QGEN) recently:

  • 9/19/2016 – Qiagen NV had its “buy” rating reaffirmed by analysts at DZ Bank AG.
  • 9/16/2016 – Qiagen NV had its “buy” rating reaffirmed by analysts at Commerzbank AG.
  • 9/14/2016 – Qiagen NV was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $29.00 price target on the stock. According to Zacks, “Post a promising second quarter show; we are encouraged by Qiagen’s constant effort to strengthen its molecular diagnostics test menu. Also, the huge potential of the global in vitro diagnostics market buoys optimism. Further, Qiagen’s expanded commercialization to the Asia-Pacific region, beyond its initial focus on Europe is another upside. The company’s commitment to pay back its shareholders through increased share repurchase program is indicative of the solid cash position it holds. On the flip side, declining U.S. HPV sales continue to impede the overall sales performance. Further, on the profitability front, Qiagen performed poorly on the back of declines in both gross and operating margins. Competitive landscape and strong reliance on collaborations also continue to be concerns.”
  • 9/13/2016 – Qiagen NV was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Qiagen’s second-quarter 2016 results squarely beat the Zacks Consensus Estimates. However, the year-over-year decline in EPS is disappointing. Nevertheless, Qiagen’s commitment to pay back its shareholders through increased share repurchase program is indicative of the solid cash position it holds. Also, Qiagen’s expanded commercialization to the Asia-Pacific region, beyond its initial focus on Europe, buoys optimism. On the flip side, declining U.S. HPV sales continue to impede the overall sales performance. Further, on the profitability front, Qiagen performed poorly on the back of declines in both gross and operating margins. The rise in operating expenses also is a headwind, although they were on account of the expansion initiatives and development programs recently adopted by Qiagen. Competitive landscape and strong reliance on collaborations also continue to be concerns.”
  • 9/12/2016 – Qiagen NV had its “buy” rating reaffirmed by analysts at DZ Bank AG.
  • 9/11/2016 – Qiagen NV was given a new $30.00 price target on by analysts at Morgan Stanley. They now have a “buy” rating on the stock.
  • 9/9/2016 – Qiagen NV had its “buy” rating reaffirmed by analysts at Commerzbank AG.
  • 8/31/2016 – Qiagen NV had its “buy” rating reaffirmed by analysts at Commerzbank AG.
  • 8/4/2016 – Qiagen NV had its “hold” rating reaffirmed by analysts at Jefferies Group.
  • 8/3/2016 – Qiagen NV was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $30.00 price target on the stock. According to Zacks, “Qiagen’s second-quarter 2016 results squarely beat the Zacks Consensus Estimates. However, the year-over-year decline in EPS is disappointing. Nevertheless, Qiagen’s commitment to pay back its shareholders through increased share repurchase program is indicative of the solid cash position it holds. Also, Qiagen’s expanded commercialization to the Asia-Pacific region, beyond its initial focus on Europe, buoys optimism. On the flip side, declining U.S. HPV sales continue to impede the overall sales performance. Further, on the profitability front, Qiagen performed poorly on the back of declines in both gross and operating margins. The rise in operating expenses also is a headwind, although they were on account of the expansion initiatives and development programs recently adopted by Qiagen. Competitive landscape and strong reliance on collaborations also continue to be concerns.”
  • 8/1/2016 – Qiagen NV had its price target raised by analysts at Mizuho from $22.00 to $25.00. They now have a “neutral” rating on the stock.
  • 8/1/2016 – Qiagen NV was upgraded by analysts at HSBC from a “hold” rating to a “buy” rating.
  • 7/29/2016 – Qiagen NV was upgraded by analysts at TheStreet from a “hold” rating to a “buy” rating.
  • 7/29/2016 – Qiagen NV had its “buy” rating reaffirmed by analysts at Commerzbank AG.
  • 7/29/2016 – Qiagen NV had its “buy” rating reaffirmed by analysts at DZ Bank AG.
  • 7/29/2016 – Qiagen NV had its “hold” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 7/25/2016 – Qiagen NV was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Qiagen continues to remain strong with sales of the company’s popular QuantiFERON-TB test that had witnessed a surge of over 25% at CER in the last reported quarter, thanks to the recent commercial initiatives adopted in the U.S. and Europe. We expect this trend in the upcoming quarters as well. Qiagen has also launched over 170 new QIAseq Targeted RNA Panels so far in 2016. Increased use of data analytics and insights into bioinformatics has propelled growth at the company. However, declining HPV sales in the U.S. continue to be a drag on the overall sales performance. Although Qiagen’s overall cash balance seems strong, weak free cash flow reserve raises further concerns. The competitive landscape and strong reliance on collaborations also remain threats.”
  • 7/25/2016 – Qiagen NV had its “neutral” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $23.00 price target on the stock.

Shares of Qiagen NV (NASDAQ:QGEN) opened at 26.45 on Thursday. Qiagen NV has a one year low of $19.94 and a one year high of $28.04. The stock has a 50 day moving average price of $26.75 and a 200-day moving average price of $23.37. The company has a market capitalization of $6.19 billion, a price-to-earnings ratio of 52.90 and a beta of 0.90.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/research-analysts-recent-ratings-updates-for-qiagen-nv-qgen.html

Qiagen NV (NASDAQ:QGEN) last announced its earnings results on Thursday, July 28th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.01. The business earned $334.40 million during the quarter, compared to analyst estimates of $326.73 million. Qiagen NV had a return on equity of 9.21% and a net margin of 9.13%. Qiagen NV’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $0.26 EPS. On average, equities research analysts expect that Qiagen NV will post $1.09 EPS for the current year.

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.

5 Day Chart for NASDAQ:QGEN

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.